Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 27;21(11):3816.
doi: 10.3390/ijms21113816.

Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo

Affiliations
Review

Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo

Gitte Holmen Olofsson et al. Int J Mol Sci. .

Abstract

Recent advances in clinical oncology is based on exploiting the capacity of the immune system to combat cancer: immuno-oncology. Thus, immunotherapy of cancer is now used to treat a variety of malignant diseases. A striking feature is that even patients with late-stage disease may experience curative responses. However, most patients still succumb to disease, and do not benefit from treatment. Exercise has gained attention in clinical oncology and has been used for many years to improve quality of life, as well as to counteract chemotherapy-related complications. However, more recently, exercise has garnered interest, largely due to data from animal studies suggesting a striking therapeutic effect in preclinical cancer models; an effect largely mediated by the immune system. In humans, physical activity is associated with a lower risk for a variety of malignancies, and some data suggest a positive clinical effect for cancer patients. Exercise leads to mobilization of cells of the immune system, resulting in redistribution to different body compartments, and in preclinical models, exercise has been shown to lead to immunological changes in the tumor microenvironment. This suggests that exercise and immunotherapy could have a synergistic effect if combined.

Keywords: cancer; exercise; immune system; immunotherapy; physical activity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Exercise-dependent regulation of immune cells and modulation of the TME. Evidence from preclinical studies shows that exercise is associated with acute mobilization and redistribution of immune cells to tumors. This supports the potential role of exercise, as a modulator of the TME into a more antitumor environment. The hypothesis of exercise as a TME modulator is indicated in the figure, such as turning a cold tumor into a hot tumor; including higher infiltration of cytotoxic immune cells, decreased infiltration of suppressor immune cells, and altered chemokine expression. Finally, this modulation of TME into a more antitumor environment, suggests that exercise and immunotherapy could have a synergistic effect if combined. TME = tumor microenvironment. NK cells = natural killer cells. MDSCs = myeloid-derived suppressor cells. Tregs = regulatory T cells.

Similar articles

Cited by

References

    1. Alsaab H.O., Sau S., Alzhrani R., Tatiparti K., Bhise K., Kashaw S.K., Iyer A.K. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front. Pharmacol. 2017;8 doi: 10.3389/fphar.2017.00561. - DOI - PMC - PubMed
    1. Sun C., Mezzadra R., Schumacher T.N. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48:434–452. doi: 10.1016/j.immuni.2018.03.014. - DOI - PMC - PubMed
    1. Hirsch L., Zitvogel L., Eggermont A., Marabelle A. PD-Loma: A cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. Br. J. Cancer. 2019;120:3–5. doi: 10.1038/s41416-018-0294-4. - DOI - PMC - PubMed
    1. Gellrich F.F., Schmitz M., Beissert S., Meier F. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update. J. Clin. Med. 2020;9:223. doi: 10.3390/jcm9010223. - DOI - PMC - PubMed
    1. Reck M., Schenker M., Lee K.H., Provencio M., Nishio M., Lesniewski-Kmak K., Sangha R., Ahmed S., Raimbourg J., Feeney K., et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: Patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur. J. Cancer. 2019;116:137–147. doi: 10.1016/j.ejca.2019.05.008. - DOI - PubMed